Studies suggest that aberrations in the expression or functionality of CD62L could potentially trigger immune disorders and onset of numerous medical conditions, spanning autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus) and infectious illnesses (like AIDS, tuberculosis) 35–38. This evidence concerns the gene SELL and rheumatoid arthritis.